Life Science Pharmaceuticals, a biopharmaceutical company, has signed a license agreement with Abbott to develop Antibody 806, which may prove to be an important tool in the fight against cancer.

 

The agreement provides Abbott with exclusive worldwide rights to Antibody 806, which targets the clinically validated pathway involving the epidermal growth factor receptor (EGFr). Antibody 806 is differentiated by its unique epitope targeting a transitional form of EGFr. Financial details of the agreement were not disclosed.

James Fiore, president and CEO of Life Science Pharmaceuticals, said: "We are delighted to have Abbott as our development partner. We are very impressed with the company's technological capabilities and its commitment to developing class-leading antibodies."